A breakdown of recent survey results revealing which benefits employers plan to keep and what they are looking to add in 2025.
Healthcare costs are on the rise, but most employers don’t plan to cut their benefits, according to the results of a recent survey by Mercer, a global consulting firm. The results of their Survey on Health and Benefit Strategies for 2025 were published yesterday.
Nearly 700 organizations participated in this survey, which was conducted earlier this year from March 21 to April 12.
Total healthcare benefit cost has increased 3% annually from 2013 to 2022, but in 2023, the cost jumped to 5.2% partly due to medical inflation. It’s estimated that costs in 2024 will be similar. Prescription drug costs rose 8.6% per employee in 2023.
Despite this, 69% of employers are still committed to boosting affordability in the next few years.
Here are some of the ways they plan to do that:
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Patient Advocacy Groups and Caretaker Diversity in Metastatic Breast Cancer Research
October 22nd 2024Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery, shares the reasons why she chose to study metastatic breast cancer patients.
Read More